You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

 

Online download statistics by month:

Online download statistics by month: March 2021 to November 2025

AbstractFullPdf
Mar 2021644644327
Apr 202132332393
May 202125525549
Jun 202122322346
Jul 202117517529
Aug 202118418441
Sep 202115215241
Oct 202119619642
Nov 202117317332
Dec 202117717728
Jan 202216917427
Feb 202214114535
Mar 2022677747
Apr 2022798026
May 2022808241
Jun 2022929339
Jul 202214214332
Aug 202212812821
Sep 202210210229
Oct 2022878828
Nov 202211711944
Dec 2022989820
Jan 2023818116
Feb 202311611727
Mar 2023727320
Apr 2023727226
May 2023777717
Jun 2023838420
Jul 2023828228
Aug 202357578
Sep 2023878723
Oct 2023767632
Nov 2023808014
Dec 2023818122
Jan 2024606336
Feb 2024949439
Mar 202412012066
Apr 202410410732
May 20249910030
Jun 202410910936
Jul 202411511733
Aug 2024908922
Sep 2024585923
Oct 2024595927
Nov 2024919237
Dec 202411211334
Jan 2025808023
Feb 2025949449
Mar 2025777735
Apr 2025808040
May 2025707137
Jun 2025494928
Jul 2025110
Aug 2025110
Sep 2025110
Nov 2025110
Total633363751997